Skip to main content

Table 4 Physician-reported new and worsened side effects during follow-up according to CTCAE classification. PRO data is reported as PROCTCAE and listed separately, hence, not included in the physician reported results

From: Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO)

CTCAE grade Pre RT (n = 219) <  6 months (n = 208) 6–12 months (n = 130) > 12 months (n = 120) PRO (n = 38)
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Pain 6 (3%) 4 (2%) 14 (7%) 4 (2%) 1 (< 1%) 6 (5%) 2 (2%) 3 (3%) 6 (5%) 1 (1%) 9 (24%) 7 (18%)
Fatigue 2 (1%) 21 (10%) 5 (2%) 4 (3%) 2 (2%) 5 (4%) 3 (3%) 9 (24%) 16 (42%)
Nausea/vomiting 1 (< 1%) 1 (1%) 1 (3%) 3 (8%)
Dermatitis 3 (1%) 1 (1%) 1 (1%) 3 (8%) 1 (3%) 1 (3%)
Hyperpigmentation 3 (1%) 2 (2%) 2 (5%)
Edema 1 (< 1%) 6 (3%) 5 (4%) 2 (2%) 3 (3%) 1 (1%) 7 (18%) 7 (18%)
Osteonecrosis, rib fracture 1 (1%)
Sensory deficits 1 (< 1%) 2 (2%) 10 (26%) 5 (13%) 1 (3%) 1 (3%)
Motor deficits 2 (1%) 2 (2%) 7 (18%) 6 (16%) 2 (5%)
Weight loss 1 (< 1%) 3 (1%) 3 (2%) 5 (4%) 4 (11%) 5 (13%) 1 (3%)
Fibrosis 1 (< 1%) 25 (12%) 3 (1%) 22 (17%) 6 (5%) 13 (11%) 2 (2%) 1 (1%)
Pneumonitis 24 (12%) 20 (10%) 1 (< 1%) 5 (4%) 3 (1%) 1 (1%) 1 (1%)
Dysphagia 2 (1%) 2 (1%) 1 (< 1%) 3 (1%) 1 (< 1%) 1 (1%) 2 (2%) 4 (3%) 10 (26%) 4 (11%) 1 (3%)
Dyspnea 17 (8%) 9 (4%) 1 (< 1%) 27 (13%) 23 (11%) 3 (1%) 5 (4%) 3 (2%) 7 (6%) 6 (5%) 10 (26%) 8 (21%) 4 (11%) 2 (5%)
Cough 15 (7%) 1 (< 1%) 35 (17%) 5 (2%) 10 (8%) 2 (2%) 15 (13%) 2 (2%) 10 (26%) 14 (37%) 1 (3%)
Xerostomia 2 (1%) 3 (1%) 1 (< 1%) 1 (1%) 1 (1%) 11 (29%) 11 (29%)
Dysphonia 1 (< 1%) 1 (< 1%) 1 (< 1%) 2 (2%) 1 (1%) 8 (21%) 4 (11%) 1 (3%)
  1. RT Radiotherapy, PRO Patient-reported outcome, CTCAE Common Terminology Criteria for Adverse Events